SNP (Single Nucleotide Polymorphism) variation site causing ABO blood group gene not conforming to genetic law
By detecting specific SNP sites in the ABO blood type system, the situation in the ABO blood type system that does not conform to Mendel's genetic law is solved, and the rapid detection of mutation sites of ABO blood type AB variant genes is achieved, which avoids blood type identification disputes. An effective clinical testing method is provided.
Patent Information
- Application Number
- CN202410934870.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-29
Smart Images

Figure CN119040470A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of gene diagnosis services, and specifically relates to a SNP site of an ABO blood type gene that does not conform to Mendel's inheritance law and an application thereof. Background Art
[0002] The ABO blood type system is controlled by three alleles (A, B, O), and the inheritance mechanism of ABO blood type can be explained according to Mendel's law of inheritance. According to the ABO blood type system, human blood types can be divided into four main types: A, B, AB and O:
[0003] 1) Type A blood: Type A blood has A antigens on the surface of red blood cells and anti-B antibodies in the plasma. Type A blood can receive blood from type A and type O, but can only donate to type A and type AB.
[0004] 2) Type B blood: Type B blood has B antigens on the surface of red blood cells and anti-A antibodies in the plasma. Type B blood can receive blood from Type B and Type O, but can only donate to Type B and Type AB.
[0005] 3) AB blood type: AB blood type has both A and B antigens on the surface of red blood cells, and the plasma does not contain anti-A or anti-B antibodies. AB blood type can receive blood from A, B, AB and O types, but can only donate to AB blood type.
[0006] 4) O blood type: O blood type has no A or B antigens on the surface of red blood cells, and the plasma contains anti-A and anti-B antibodies. O blood type can receive blood from any blood type, but can only donate to O blood type.
[0007] In the ABO blood group system, the A and B genes are co-dominant, while the O gene is recessive. This means that when the O gene is inherited, it will only be expressed when both alleles are O genes.
[0008] 1. Genotype and phenotype
[0009] ①People with A / A or A / O genotype have "A blood type".
[0010] ②People with B / B or B / O genotype have "B blood type".
[0011] ③People with A / B genotype have "AB blood type" because the A and B genes are co-dominant.
[0012] ④People with O / O genotype have “O blood type”.
[0013] Once the blood type and genotype of both parents are determined, the probability of their children's blood type can be predicted by Mendel's laws of inheritance (including the law of segregation and the law of independent assortment).
[0014] ① Law of segregation: Each individual has two alleles, which separate when forming germ cells, and each germ cell gets only one.
[0015] ②Law of independent assortment: Alleles with different characteristics are independently distributed when gametes are formed. Therefore, the genetic combination of ABO blood type is determined by an allele contributed by each parent.
[0016] If the father's blood type is A (the possible genotypes are A / A or A / O) and the mother's blood type is B (the possible genotypes are B / B or BO / ), then their children's possible blood types are A (from the father's A and the mother's O), B (from the mother's B and the father's O), AB (from the father's A and the mother's B) or O (from both O). Through the probability calculation of Mendel's law of inheritance, the probability of each blood type can be specifically analyzed. Through this genetic mechanism, the ABO blood type system shows the diversity and complexity of inheritance. Understanding the genetic mechanism of ABO blood type is not only of great significance to the medical field, but also an important example of exploring the basic principles of human genetics.
[0017] The inheritance of ABO blood type genes usually follows Mendel's laws of inheritance, but in some special cases, the inheritance of phenotypes seems to "violate" these basic laws. These situations often involve other complex mechanisms of genetics rather than truly violating Mendel's laws. The following are some situations that may cause ABO blood type inheritance to appear to violate the laws of inheritance:
[0018] 1. Gene mutation: Gene mutation can change the expression of alleles, thus affecting blood type. For example, an individual who should be type A may phenotypically be type O due to gene mutation.
[0019] 2. Incomplete dominance of dominant genes: Although the A and B genes are dominant over the O gene, in rare cases, the expression of the A or B gene may be incomplete, resulting in atypical blood type characteristics.
[0020] 3. Genetic recombination and random events: During the formation of gametes, the recombination and random distribution of chromosomes may lead to different combinations of genetic material, which in most cases follows Mendel's law of free combination. However, in rare cases, abnormal chromosome distribution may lead to abnormal genetic phenotypes.
[0021] 4. Polygenic inheritance: Although ABO blood type is mainly controlled by a single locus, other genes and genetic factors may also affect the expression of blood type phenotype, such as affecting antigen synthesis and expression.
[0022] 5. Influence of external factors: Certain diseases or environmental factors may affect the expression of blood type antigens. Although this does not change the individual's genotype, it may affect the phenotypic detection of blood type.
[0023] 6. Chimera blood type: In very rare cases, such as chimerism or blood transfusion, a blood type phenotype that does not match the individual's genetic genotype may appear in the individual's blood.
[0024] Although these cases are rare, they are important aspects of genetic research and help us better understand the complexity of genetic mechanisms. In most cases, the inheritance of ABO blood types follows Mendel's laws, and these exceptions remind us of the diversity and complexity of biological genetics. Summary of the invention
[0025] The present invention provides a SNP site that causes a variant of the ABO blood type system that does not conform to Mendel's genetic law and an application thereof, thereby making up for the deficiencies of the prior art by detecting the SNP site.
[0026] The present invention provides a SNP site of an ABO blood group system variant that does not conform to Mendel's genetic law, wherein the SNP site comprises a heterozygous mutation of CG at position 411 and a heterozygous mutation of GC at position 454 of a nucleic acid fragment having a sequence of SEQ ID NO: 1;
[0027] The present invention also provides a use of the SNP site as a molecular marker for detecting AB variant alleles of the ABO blood group system;
[0028] The present invention also provides a use of the preparation for detecting the SNP site, which is used in preparing a preparation for detecting AB variant alleles of the ABO blood group system;
[0029] The products described above are one type of PCR amplification sequencing kit;
[0030] The preparation for detecting SNP sites is a PCR amplification sequencing primer pair or a detection probe;
[0031] The direct amplification and sequencing primer information used to detect the above SNP sites are as follows: ABO-E7F: 5'-TGGCGGGCGGGTGCAGGA-3' SEQ ID NO: 2, ABO-E7R: 5'-CACAACAGGACGGACAAAGGA-3' SEQ ID NO: 3;
[0032] The primer information used to detect the haplotype amplification of the above-mentioned SNP sites is as follows. The sequencing primers use the corresponding primers of the dedicated vector for efficient cloning of PCR products (pMD18-T vector): ABO-E7Fmo: 5'-CCCGGTATTCCGCATCAC-3'SEQ ID NO:4, ABO-E7mo: 5'-CGGTGTAGCCTCCTGTCCAT-3'SEQ ID NO:5.
[0033] The present invention provides a SNP site of an ABO blood type system variant that does not conform to Mendel's laws of inheritance, thereby providing an effective way to avoid disputes and social problems caused by situations that do not conform to Mendel's laws of inheritance in blood type identification. The application effect shows that the SNP site of the gene and the detection primer provided by the present invention can be effectively used for rapid detection of ABO blood type AB variant gene mutation sites in the peripheral blood of clinical patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 : ABO blood type normal ABO*B1.02 allele reference sequence, the reference sequence comes from BGMUT (International Blood Type Gene Mutation Database);
[0035] Figure 2 : Direct sequencing of the proband's AB subtype variant gene mutation site;
[0036] Figure 3 :Sequencing map of the proband's clone. The proband's ABO gene coding region has mutations c.700C>G and c.743G>C at the 700th and 743rd bases from the start codon. (ABO*B1.01 is used as the reference sequence) DETAILED DESCRIPTION
[0037] The proband of the present invention is Li, who was promoted from kindergarten to elementary school. During the physical examination in the designated hospital, it was found that the blood type of Li and his parents did not conform to the Mendel's inheritance law. Li was AB type, his father was AB type, and his mother was O type. After the ABO blood type gene molecular detection, a pathogenic SNP site was found in the family of ABO blood type AB variant allele, and it was confirmed that the mutation of the gene caused the blood type to mutate. The B gene can only encode B antigen to form B type, but the variant allele causes the allele to encode both A antigen and B antigen. The proband's red blood cells have both A antigen and B antigen, which is weaker than the A antigen of normal A-type human red blood cells, and the same anti-A1 antibody is produced in the plasma. Serological detection is easily typed as AB type, and the positive and negative typing of the proband and parents' ABO blood type identification is inconsistent (Table 1).
[0038] Table 1: Information of ABO blood types of the proband and his parents
[0039] -A -B Ac Bc Oc Self cells Blood type results Proband 2+ 4+ 1+ 0 0 0 Suspected AB type Father of the proband 2+ 4+ 1+w 0 0 0 Suspected AB type Mother of the proband 0 0 4+ 3+ 0 0 Type O
[0040] The family members who had the proband's dominant AB variant allele on autosome 9q34.1-9q34.2 were sequenced, and the genetic pathogenic mutation SNP site of the AB variant allele in the family members was found. This SNP site caused the production of A antigen on the red blood cells of the originally B-type individuals, and anti-A antibodies could be produced through immune stimulation or naturally.
[0041] The AB variant allele is located on chromosome 9q34.1-9q34.2 (NCBI accession number NM_020469.2). The SNP site found is located in the coding region of the AB variant allele of the ABO blood type. The 700th and 743rd bases of Exon7 from the start codon have mutations c.700C>G; c.743G>C, which are located at positions 411 and 454 of the sequence SEQ ID NO:1 (marked in bold letters).
[0042] TGGCGGGCGGGTGCAGGACGGGCCTCCTGCAGCCCAGGGGTGCACGGCCGGCGGCTCCCCCAGCCCCCGTCCGCCTGCCTTGCAGATACGTGGCTTTCCTGAAGCTGTTCCTGGAGACGGCGGAGAAGCACTTCATGGTGGGCCACCGTGTCCACTACTATGTCTTCACCGACCAGCCGGCCGCGGTGCCCCGCGTGACGCTGGGGACCGGTCGGCAGCTGTCAGTGCTGGAGGTGGGCGCCTACAAGCGCTGGCAGGACGTGTCCATGCGCCGCATGGAGATGATCAGTGACTTCTGCGAGCGGCGCTTCCTCAGCGAGGTGGATTACCTGGTGTGCGTGGACGTGGACATGGAGTTCCGCGACCATGTGGGCGTGGAGATCCTGACTCCGCTGTTCGGCACCCTGCACGCCAGCTTCTACGGAAGCAGCCGGGAGGCCTTCACCTACGAGCCCCGGCCCCAGTCCCAGGCCTACATCCCCAAGGACGAGGGCGATTTCTACTACATGGGGGCGTTCTTCGGGGGGTCGGTGCAAGAGGTGCAGCGGCTCACCAGGGCCTGCCACCAGGCCATGATGGTCGACCAGGCCAACGGCATCGAGGCCGTGTGGCACGACGAGAGCCACCTGAACAAGTACCTACTGCGCCACAAACCCACCAAGGTGCTCTCCCCCGAGTACTTGTGGGACCAGCAGCTGCTGGGCTGGCCCGCCGTCCTGAGGAAGCTGAGGTTCACTGCGGTGCCCAAGAACCACCAGGCGGTCCGGAACCCGTGAGCGGCTGCCAGGGGCTCTGGGAGGGCTGCCGGCAGCCCCGTCCCCCTCCCGCCCTTGGTTTTAGCAGAACGGGTAAACTCTGTTTCCTTTGTCCGTCCTGTTGTG(SEQ IDNO:1).
[0043] The present invention will be described in detail below in conjunction with the embodiments and the accompanying drawings.
[0044] Example 1: Confirmation of the mutation site of the AB variant allele from the proband's ABO blood type gene test.
[0045] 1. Extraction of peripheral blood genomic DNA:
[0046] In accordance with relevant national policies and regulations, and based on the consent of the sampling subjects, 2-5 ml of peripheral venous blood from ABO blood type A variant gene family members was drawn, placed in EDTA-Na2 anticoagulant tubes, and frozen at -80°C for future use; DNA extraction was performed using the DNA extraction kit of LIFE Company. The specific operation process is as follows:
[0047] After the frozen EDTA anticoagulated blood is thawed at room temperature, take 500ul and put it in a centrifuge tube, add an equal volume of red blood cell lysis solution (pH8.0), vortex mix for 5 minutes, centrifuge at 12000rpm for 5 minutes, and discard the supernatant. Repeat adding 500ul of red blood cell lysis solution, vortex mix for 5 minutes, centrifuge at 12000rpm for 5 minutes, and discard the supernatant.
[0048] Vortex the precipitate for 5 minutes, add 50ul of nuclear lysis solution, vortex for 5 minutes, and place in a 56℃ metal bath for 15 minutes. Remove the sample from the water bath and add 135ul of protein clearing solution. Vortex thoroughly and incubate at 4℃ for 30 minutes.
[0049] Centrifuge at 12000rpm for 5 minutes at room temperature, and pipette the supernatant (about 200ul) into a new centrifuge tube. Add 500ul of ice ethanol and shake the centrifuge tube repeatedly until the white DNA precipitate is precipitated. Centrifuge at 12000rpm for 2 minutes at room temperature and discard the supernatant. Add 75% ethanol to the DNA precipitate, rinse once, centrifuge at 12000rpm for 3 minutes at room temperature, discard the supernatant, and place at room temperature to evaporate the remaining ethanol. Finally, add 50μLTE (pH8.0) and dissolve the DNA at 4℃ overnight.
[0050] The extracted DNA was subjected to agarose gel electrophoresis, and the purity and concentration of the DNA were detected by ultraviolet spectrophotometer at 260nm and 280nm.
[0051] 2. Direct sequencing to find the mutation site of the proband's AB variant allele
[0052] PCR amplification of target fragments: reaction conditions and reaction system:
[0053] (1) PCR reaction conditions: pre-denaturation at 95°C for 10 min; 10 cycles of 94°C for 60 s, 63°C for 90 s, and 72°C for 60 s; 25 cycles of 94°C for 60 s, 61°C for 90 s, and 72°C for 60 s; extension at 72°C for 10 min, and incubation of the amplified product at 10°C.
[0054] (2) Reaction system: (TAKARAEx-Taq polymerase)
[0055]
[0056] This reaction system was used to perform an amplification reaction using the proband's genomic DNA template and the above-mentioned ABO-E7F and ABO-E7R primers.
[0057] PCR product sequencing: The PCR product was sequenced using the conventional Sanger sequencing method, using primer pair ABO-E7F: 5'-TGGCGGGCGGGTGCAGGA-3'; ABO-E7R: 5'-CACAACAGGACGGACAAAGGA-3', and the most common ABO*B1.01 allele in Chinese as the reference sequence. Mutations c.700C>G; c.743G>C were found at base 700 and base 743 of Exon7 in the proband. Using ABO-E7F as the forward sequencing primer and ABO-E7R as the reverse sequencing primer, multiple forward and reverse sequencing results showed that the mutation site did exist and was not introduced due to amplification or sequencing errors ( Figure 2 ).
[0058] Example 2 Verification of SNP sites
[0059] Haplotype sequencing of exon 7 of the ABO gene was performed to determine the mutation site of the proband's AB variant allele.
[0060] PCR amplification target fragment primers:
[0061] ABO-E7F:5'-TGGCGGGCGGGTGCAGGA-3';
[0062] ABO-E7R:5'-CACAACAGGACGGACAAAGGA-3'.
[0063] PCR amplification primers may also be selected from other primer pairs that can amplify the above-mentioned SNP sites.
[0064] Reaction conditions and reaction system for PCR amplification of target fragments:
[0065] (1) PCR reaction conditions: pre-denaturation at 95°C for 5 min; 40 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 50 s; extension at 72°C for 5 min, and incubation of the amplified product at 10°C.
[0066] (2) Reaction system: (TAKARALA-Taq polymerase)
[0067]
[0068] The reaction system was used to perform amplification reactions on the genomic DNA template of each family member and the primers designed by the inventor for cloning and sequencing. The PCR product was cloned into a T vector, and multiple colonies were selected for haplotype sequence determination. The haplotype sequencing primers were used.
[0069] ABO-E7Fmo: 5'-CCCGGTATTCCGCATCAC-3',
[0070] ABO-E7Rmo: 5'-CGGTGTAGCCTCCTGTCCAT-3' to determine the haplotype sequence of the sample ( Figure 3 ). This mutation is a newly discovered mutation. This mutation does not exist in the following three databases: Single Nucleotide Polymorphism Database (ftp: / / ftp.ncbi.nih.gov / snp / database / ), Blood Type Gene Mutation Database (http: / / www.ncbi.nlm.nih.gov / projects / gv / mhc / xslcgi.fcgi?cmd=bgmut / systems_info&system=abo), indicating that this mutation is very rare. This mutation causes the nucleotides of the protein encoding the B antigen to change. The protein can catalyze the production of A antigen and B antigen. The gene coding region has mutations at the 700th and 743rd bases of the start codon Exon7, c.700C>G; c.743G>C. The mutations will cause the 233rd and 247th amino acids to mutate from proline to alanine, respectively; the arginine to mutate from proline to proline. The mutation of amino acids causes the individuals of this AB subtype to produce partial epitopes of A antigen, causing such individuals to produce the same anti-A1 antibodies in plasma through immune stimulation or natural immunity, thus producing suspected AB type.
[0071] The peripheral blood genomic DNA of the proband's family members collected by the applicant was extracted, and the above DNA was used as a template to amplify the PCR target fragment with ABO-E7F and ABO-E7R primers. The conventional Sanger sequencing method was used to directly sequence the PCR product using the above pair of primers. It was found that the ABO blood type AB variant gene of a family member of the proband (the proband's father) had the SNP mutation discovered in the present invention, and the gene coding region had mutations c.700C>G and c.743G>C at the 700th base and 743rd base of the start codon Exon7.
[0072] Through the above analysis, it is proved that the primers designed by the inventor can be used to detect whether an individual's ABO blood type gene has the above-mentioned AB subtype allele that violates Mendel's law of inheritance.
Claims
1. A SNP site, characterized in that: The SNP site includes a heterozygous mutation of CG at position 411 and a heterozygous mutation of GC at position 454 in the nucleic acid fragment with the sequence of SEQ ID NO:
1.
2. Use of the SNP site described in claim 1 as a molecular marker for detecting AB variant alleles of the ABO blood group system.
3. An application of the preparation for detecting the SNP site according to claim 1, characterized in that: The application is the application in preparing products for detecting AB variant alleles of the ABO blood group system.
4. The use according to claim 3, characterized in that The product is a PCR amplification sequencing kit.
5. The use according to claim 3, characterized in that The preparation for detecting the SNP site according to claim 1 is a PCR amplification sequencing primer pair or a detection probe.
6. The use according to claim 4, characterized in that The sequences of the upstream and downstream primers of the primer pair are SEQ ID NO: 2 and SEQ ID NO:
3.
7. The use according to claim 4, characterized in that The sequences of the upstream and downstream primers of the primer pair are SEQ ID NO:4 and SEQ ID NO:
5.
8. A molecular detection product for detecting AB variant alleles of the ABO blood group system, characterized in that: The product comprises a primer pair for detecting the SNP site according to claim 1.
9. The molecular detection product according to claim 8, characterized in that The sequences of the upstream and downstream primers of the primer pair are SEQ ID NO: 2 and SEQ ID NO:
3.
10. The molecular detection product according to claim 8, characterized in that The sequences of the upstream and downstream primers of the primer pair are SEQ ID NO:4 and SEQ ID NO:5.
